Omicia Rebrands as Fabric Genomics

Fabric Enterprise Delivers Secondary Analysis, Interpretation and Reporting for Clinically Meaningful Insights

Oakland, CA and Phoenix, AZ — Omicia today announced that it has rebranded and renamed the organization to better reflect the company’s ability to uniquely deliver clinical quality genomic data insights. Now known as Fabric Genomics TM, the company revealed its new name, logo and brand identity at this week’s ACMG Annual Clinical Genetics Meeting. The company also launched Fabric EnterpriseTM, an optimized computational genomics platform enabling secondary analysis, rapid annotation, guideline-driven variant classification and clinical reporting for both hereditary disease and oncology.

“As a result of our recent acquisition, related capability expansions and technology partnerships, it was time to re-imagine our company’s broader role in the future of healthcare,” said Matt Tindall, Chief Executive Officer of Fabric Genomics. “We are at the precipice of low-cost, real-time access to our personal genomic data—or unique molecular operating system (MOS) data. We believe the MOS data will soon become a foundational element in every patient’s interaction with the systems of healthcare, like blood type or family history. Our role, along with our partners, is to secure, manage, analyze, interpret and weave genetic data into the fabric of healthcare to drive behavior change, cost efficiency and better outcomes. The idea that we can unlock genetic information unlike any other company, to inform important healthcare decisions, gave rise to Fabric Genomics.”

Genome sequencing costs continue to experience record-breaking declines. Consequently, this means, that significant amounts of raw genomic data are generated. Despite these technology advances, clinical application is dependent on many disparate, disconnected genomic data analysis and interpretation platforms expected to deliver consistent, high quality and meaningful insights. With the launch of Fabric Enterprise, any commercial clinical or hospital laboratory can use one platform behind any sequencer to translate raw data from panels, exomes or whole genomes into robust clinical reports.

Martin Reese, Ph.D., Chief Scientific Officer, Co-Founder and President at Fabric Genomics, said, “In the industry, existing in-house and external solutions often provide either single algorithms for genomes or engineering pipelines tight to specific small gene panels. They may be sequencing-platform dependent or address only one piece of the analysis and reporting workflow. Fabric Genomics now offers a complete, all-in-one integrated solution including capabilities that support secondary and tertiary genome analysis to reporting and clinical workflow integration in hospitals and clinical labs to truly improve care for patients.”

The Fabric Genomics rebrand follows several triumphant milestones for the company, including a Series B financing round, newly signed strategic partners, the acquisition of Spiral Genetics and the launch of somatic cancer capabilities. Over the past 12 months, the company has grown from a world-class tertiary analysis vendor mostly serving research and undiagnosed hereditary disease markets, to a full-scale, end-to-end computational genomics company serving the clinical community.

This week at the ACMG Annual Clinical Genetics Meeting, Fabric Genomics will give a corporate presentation on Friday, March 24 at 12:30 p.m. This talk, among several other presentations and posters, will feature progress on pediatric genomic data reporting, including cases managed under the direction of Stephen Kingsmore, M.D., D.Sc. at Rady’s Children’s Institute for Genomic Medicine in San Diego, California.

About Fabric Genomics
Fabric GenomicsTM is a computational genomics company offering end-to-end genomic data analysis, annotation, curation, classification and reporting solutions to clinical labs, hospital labs, country sequencing programs and life science companies. Fabric Genomics’ analytic capabilities begin with raw data analysis and include the delivery of rapid, comprehensive insights for high throughout panels, exomes, and whole genomes. The company can process any NGS file input (e.g. FASTQ, BAM or VCF) providing alignment, variant calling, annotation, guideline-driven variant classification, variant interpretation and clinical reporting for both hereditary disease and oncology. Fabric Genomics was founded by scientists and industry pioneers in bioinformatics, large-scale genomics and molecular diagnostics, and is headquartered in Oakland, California with satellite offices in London, Seattle, Salt Lake City and Boston. By accelerating access to insights related to the cause of genetic diseases, Fabric Genomics is leading the way in precision healthcare.

< Back to News & Events